5.99 USD
+0.15 (+2.57%)
5.99 USD
0 (0%)
MNKD gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. Both the profitability and the financial health of MNKD get a neutral evaluation. Nothing too spectacular is happening here. MNKD is growing strongly while it is still valued neutral. This is a good combination!
1. Profitability
1.1 Basic Checks
In the past year MNKD was profitable.
MNKD had a positive operating cash flow in the past year.
In the past 5 years MNKD reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: MNKD reported negative operating cash flow in multiple years.
1.2 Ratios
MNKD's Return On Assets of 5.81% is amongst the best of the industry. MNKD outperforms 92.08% of its industry peers.
MNKD has a Return On Invested Capital of 18.48%. This is amongst the best in the industry. MNKD outperforms 97.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.81% | ||
| ROE | N/A | ||
| ROIC | 18.48% |
ROA(3y)-8.37%
ROA(5y)-20.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MNKD's Profit Margin of 9.16% is amongst the best of the industry. MNKD outperforms 90.75% of its industry peers.
MNKD has a Operating Margin of 27.48%. This is amongst the best in the industry. MNKD outperforms 96.23% of its industry peers.
MNKD's Gross Margin of 78.49% is amongst the best of the industry. MNKD outperforms 84.72% of its industry peers.
MNKD's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.48% | ||
| PM (TTM) | 9.16% | ||
| GM | 78.49% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.44%
GM growth 5Y5.99%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), MNKD is creating value.
MNKD has more shares outstanding than it did 1 year ago.
MNKD has more shares outstanding than it did 5 years ago.
The debt/assets ratio for MNKD has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -5.19, we must say that MNKD is in the distress zone and has some risk of bankruptcy.
MNKD's Altman-Z score of -5.19 is on the low side compared to the rest of the industry. MNKD is outperformed by 62.83% of its industry peers.
MNKD has a debt to FCF ratio of 8.39. This is a slightly negative value and a sign of low solvency as MNKD would need 8.39 years to pay back of all of its debts.
The Debt to FCF ratio of MNKD (8.39) is better than 90.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 8.39 | ||
| Altman-Z | -5.19 |
ROIC/WACC2.19
WACC8.45%
2.3 Liquidity
MNKD has a Current Ratio of 3.29. This indicates that MNKD is financially healthy and has no problem in meeting its short term obligations.
MNKD has a Current ratio of 3.29. This is in the lower half of the industry: MNKD underperforms 61.13% of its industry peers.
A Quick Ratio of 3.04 indicates that MNKD has no problem at all paying its short term obligations.
The Quick ratio of MNKD (3.04) is worse than 61.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.29 | ||
| Quick Ratio | 3.04 |
3. Growth
3.1 Past
MNKD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 174.00%, which is quite impressive.
The Revenue has grown by 17.44% in the past year. This is quite good.
MNKD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 35.29% yearly.
EPS 1Y (TTM)174%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%235%
Revenue 1Y (TTM)17.44%
Revenue growth 3Y55.86%
Revenue growth 5Y35.29%
Sales Q2Q%17.2%
3.2 Future
The Earnings Per Share is expected to grow by 52.41% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 18.25% on average over the next years. This is quite good.
EPS Next Y-0.55%
EPS Next 2Y17.07%
EPS Next 3Y35.31%
EPS Next 5Y52.41%
Revenue Next Year20.91%
Revenue Next 2Y21.56%
Revenue Next 3Y18.34%
Revenue Next 5Y18.25%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 42.79, the valuation of MNKD can be described as expensive.
91.13% of the companies in the same industry are more expensive than MNKD, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of MNKD to the average of the S&P500 Index (26.61), we can say MNKD is valued expensively.
MNKD is valuated quite expensively with a Price/Forward Earnings ratio of 54.63.
Compared to the rest of the industry, the Price/Forward Earnings ratio of MNKD indicates a rather cheap valuation: MNKD is cheaper than 90.38% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 24.01. MNKD is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 42.79 | ||
| Fwd PE | 54.63 |
4.2 Price Multiples
MNKD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MNKD is cheaper than 94.15% of the companies in the same industry.
MNKD's Price/Free Cash Flow ratio is rather cheap when compared to the industry. MNKD is cheaper than 92.83% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 42.39 | ||
| EV/EBITDA | 18.26 |
4.3 Compensation for Growth
MNKD's earnings are expected to grow with 35.31% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.07%
EPS Next 3Y35.31%
5. Dividend
5.1 Amount
No dividends for MNKD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
5.99
+0.15 (+2.57%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners57.05%
Inst Owner Change2.16%
Ins Owners1.6%
Ins Owner Change-0.5%
Market Cap1.84B
Revenue(TTM)313.79M
Net Income(TTM)28.75M
Analysts85.33
Price Target9.24 (54.26%)
Short Float %7.33%
Short Ratio5.59
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)53.26%
Min EPS beat(2)-100%
Max EPS beat(2)206.52%
EPS beat(4)1
Avg EPS beat(4)19.34%
Min EPS beat(4)-100%
Max EPS beat(4)206.52%
EPS beat(8)2
Avg EPS beat(8)-31.68%
EPS beat(12)5
Avg EPS beat(12)-2.87%
EPS beat(16)6
Avg EPS beat(16)-4.99%
Revenue beat(2)1
Avg Revenue beat(2)-2.11%
Min Revenue beat(2)-4.55%
Max Revenue beat(2)0.33%
Revenue beat(4)3
Avg Revenue beat(4)-0.74%
Min Revenue beat(4)-4.55%
Max Revenue beat(4)0.9%
Revenue beat(8)6
Avg Revenue beat(8)1.65%
Revenue beat(12)8
Avg Revenue beat(12)2.45%
Revenue beat(16)11
Avg Revenue beat(16)3.58%
PT rev (1m)-12.72%
PT rev (3m)-14.34%
EPS NQ rev (1m)48.71%
EPS NQ rev (3m)-35.33%
EPS NY rev (1m)-16%
EPS NY rev (3m)-41.29%
Revenue NQ rev (1m)0.17%
Revenue NQ rev (3m)11.85%
Revenue NY rev (1m)5.89%
Revenue NY rev (3m)4.46%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 42.79 | ||
| Fwd PE | 54.63 | ||
| P/S | 5.86 | ||
| P/FCF | 42.39 | ||
| P/OCF | 37.65 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 18.26 |
EPS(TTM)0.14
EY2.34%
EPS(NY)0.11
Fwd EY1.83%
FCF(TTM)0.14
FCFY2.36%
OCF(TTM)0.16
OCFY2.66%
SpS1.02
BVpS-0.15
TBVpS-0.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.81% | ||
| ROE | N/A | ||
| ROCE | 22.37% | ||
| ROIC | 18.48% | ||
| ROICexc | 48.2% | ||
| ROICexgc | 50.4% | ||
| OM | 27.48% | ||
| PM (TTM) | 9.16% | ||
| GM | 78.49% | ||
| FCFM | 13.83% |
ROA(3y)-8.37%
ROA(5y)-20.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.44%
GM growth 5Y5.99%
F-Score8
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 8.39 | ||
| Debt/EBITDA | 3.59 | ||
| Cap/Depr | 64.99% | ||
| Cap/Sales | 1.74% | ||
| Interest Coverage | 9.12 | ||
| Cash Conversion | 51.63% | ||
| Profit Quality | 150.89% | ||
| Current Ratio | 3.29 | ||
| Quick Ratio | 3.04 | ||
| Altman-Z | -5.19 |
F-Score8
WACC8.45%
ROIC/WACC2.19
Cap/Depr(3y)397.13%
Cap/Depr(5y)337.1%
Cap/Sales(3y)10.78%
Cap/Sales(5y)10.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)174%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%235%
EPS Next Y-0.55%
EPS Next 2Y17.07%
EPS Next 3Y35.31%
EPS Next 5Y52.41%
Revenue 1Y (TTM)17.44%
Revenue growth 3Y55.86%
Revenue growth 5Y35.29%
Sales Q2Q%17.2%
Revenue Next Year20.91%
Revenue Next 2Y21.56%
Revenue Next 3Y18.34%
Revenue Next 5Y18.25%
EBIT growth 1Y48.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y237.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y386.62%
OCF growth 3YN/A
OCF growth 5YN/A
MANNKIND CORP / MNKD FAQ
What is the fundamental rating for MNKD stock?
ChartMill assigns a fundamental rating of 5 / 10 to MNKD.
What is the valuation status for MNKD stock?
ChartMill assigns a valuation rating of 5 / 10 to MANNKIND CORP (MNKD). This can be considered as Fairly Valued.
Can you provide the profitability details for MANNKIND CORP?
MANNKIND CORP (MNKD) has a profitability rating of 5 / 10.
Can you provide the expected EPS growth for MNKD stock?
The Earnings per Share (EPS) of MANNKIND CORP (MNKD) is expected to decline by -0.55% in the next year.